[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574635":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":49,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":20,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":20,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sintilimab + SOX\u002FXELOX","EXPERIMENTAL","The study only has one experimental cohort that the subjects who enter the study will receive Sintilimab combined with SOX\u002FXELOX up to 8 cycles, and then receive Sintilimab combined with Tegafur, Gimeracil and Oteracil Potassium Capsules or Capecitabine up to a year ( totally 16 cycles).",[13],"Biological: Sintilimab plus Chemotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Sintilimab plus Chemotherapy","chemotherapy includes SOX and XELOX",[9],null,[22],{"name":23,"affiliation":5,"role":24},"LIN YANG, Doctor","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","010-13681015148","linyangcicams@126.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46,48],{"name":47,"role":27,"phone":28,"phoneExt":20,"email":29},"LIN YANG",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":47,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Doctor","100574635","phase-2-sintilimab-combined-with-chemotherapy-as-adjuvant-treatment-for-phase-iii-gc-and-gej-100574635",false,"NCT06761846","Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ","A Phase II Study of Sintilimab Combined With Chemotherapy as Postoperative Adjuvant Treatment for Phase III Gastric Adenocarcinoma (GC) and The Adenocarcinoma of Esophagogastric Junction (GEJ)","Inclusion Criteria:\n\n1. Age ≥18.\n2. Patients with histopathological confirmed gastric\u002FGEJ adenocarcinoma.\n3. The pTNM is confirmed between IIIA-IIIC and the PD-L1 CPS\\>=1.\n4. Patients treated with D2 surgery.\n5. ECOG is 0 or 1.\n6. Patients who could tolerate chemotherapy combined with immunotherapy.\n7. Patients who are not pregnant and have no willing to get pregnant within 6 months after the treatment is over.\n8. Patients who are willing to offer their postoperative tumor tissue and their peripheral blood samples.\n9. Patients who are volunteer to sign the ICF.\n\nExclusion Criteria:\n\n1. Patients who had received neoadjuvent treatments before surgery.\n2. Patients who have discovered tumor relapse or metastasis before adjuvent treatment.\n3. Patients who have other malignant tumors.\n4. Patients who could not swallow the tablets and capsules.\n5. Other conditions which the researchers think are not suitable for participate the study.","ALL","18 Years",{"count":61,"type":62},70,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC\u002FGEJ adenocarcinoma after D2 or broader radical resection. After enrolling in the study, the subjects receive Sintilimab combined with oxaliplatin+Tegafur, Gimeracil and Oteracil Potassium Capsules (SOX) or oxaliplatin+Capecitabine (XELOX) , in which the combined chemotherapy is up to 8 cycles, and the total course of treatment was 16 cycles. The following-up of subjects includes adverse events、disease status、living conditions and the quality of life.",[68,69],"Gastric Adenocarcinoma","Esophagogastric Junction Adenocarcinoma","2026-04-19",{"date":72,"type":73},"2026-04-21","ACTUAL",{"date":75,"type":73},"2025-01-17",{"date":77,"type":62},"2028-12-31",{"name":5,"class":6},1]